Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial. BG-12 (dimethyl fumarate) tablets …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

